Literature DB >> 27267203

Questions regarding the safety and duration of immunity following live yellow fever vaccination.

Ian J Amanna1, Mark K Slifka2.   

Abstract

INTRODUCTION: The World Health Organization (WHO) and other health agencies have concluded that yellow fever booster vaccination is unnecessary since a single dose of vaccine confers lifelong immunity. Areas covered: We reviewed the clinical studies cited by health authorities in their investigation of both the safety profile and duration of immunity for the YFV-17D vaccine and examined the position that booster vaccination is no longer needed. We found that antiviral immunity may be lost in 1-in-3 to 1-in-5 individuals within 5 to 10 years after a single vaccination and that children may be at greater risk for primary vaccine failure. The safety profile of YFV-17D was compared to other licensed vaccines including oral polio vaccine (OPV) and the rotavirus vaccine, RotaShield, which have subsequently been withdrawn from the US and world market, respectively. Expert commentary: Based on these results and recent epidemiological data on vaccine failures (particularly evident at >10 years after vaccination), we believe that current recommendations to no longer administer YFV-17D booster vaccination be carefully re-evaluated, and that further development of safer vaccine approaches should be considered.

Entities:  

Keywords:  Yellow fever virus; antibody duration; flaviviruses; immunity; neurotropic; vaccination; viscerotropic

Mesh:

Substances:

Year:  2016        PMID: 27267203      PMCID: PMC5171234          DOI: 10.1080/14760584.2016.1198259

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.683


  101 in total

1.  Cutting edge: long-term B cell memory in humans after smallpox vaccination.

Authors:  Shane Crotty; Phil Felgner; Huw Davies; John Glidewell; Luis Villarreal; Rafi Ahmed
Journal:  J Immunol       Date:  2003-11-15       Impact factor: 5.422

2.  Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX.

Authors:  Scott Kitchener
Journal:  Vaccine       Date:  2004-06-02       Impact factor: 3.641

3.  Duration of humoral immunity to common viral and vaccine antigens.

Authors:  Ian J Amanna; Nichole E Carlson; Mark K Slifka
Journal:  N Engl J Med       Date:  2007-11-08       Impact factor: 91.245

4.  Poisson-model analysis of the risk of vaccine-associated paralytic poliomyelitis in Japan between 1971 and 2000.

Authors:  Lixin Hao; Satoshi Toyokawa; Yasuki Kobayashi
Journal:  Jpn J Infect Dis       Date:  2008-03       Impact factor: 1.362

5.  Intussusception among infants given an oral rotavirus vaccine.

Authors:  T V Murphy; P M Gargiullo; M S Massoudi; D B Nelson; A O Jumaan; C A Okoro; L R Zanardi; S Setia; E Fair; C W LeBaron; M Wharton; J R Livengood; J R Livingood
Journal:  N Engl J Med       Date:  2001-02-22       Impact factor: 91.245

6.  Poliomyelitis prevention in the United States: introduction of a sequential vaccination schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Authors: 
Journal:  MMWR Recomm Rep       Date:  1997-01-24

7.  The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response.

Authors:  Rama S Akondy; Nathan D Monson; Joseph D Miller; Srilatha Edupuganti; Dirk Teuwen; Hong Wu; Farah Quyyumi; Seema Garg; John D Altman; Carlos Del Rio; Harry L Keyserling; Alexander Ploss; Charles M Rice; Walter A Orenstein; Mark J Mulligan; Rafi Ahmed
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

8.  A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE.

Authors:  Alfred von Krempelhuber; Jens Vollmar; Rolf Pokorny; Petra Rapp; Niels Wulff; Barbara Petzold; Amanda Handley; Lyn Mateo; Henriette Siersbol; Herwig Kollaritsch; Paul Chaplin
Journal:  Vaccine       Date:  2009-11-25       Impact factor: 3.641

9.  [Yellow fever virus 17D neutralising antibodies in vaccinated Colombian people and unvaccinated ones having immunity against dengue].

Authors:  Sergio Y Gómez; Raquel E Ocazionez
Journal:  Rev Salud Publica (Bogota)       Date:  2008 Nov-Dec

10.  Low Thymic Activity and Dendritic Cell Numbers Are Associated with the Immune Response to Primary Viral Infection in Elderly Humans.

Authors:  Axel Ronald Schulz; Julia Nora Mälzer; Cristina Domingo; Karsten Jürchott; Andreas Grützkau; Nina Babel; Mikalai Nienen; Tomas Jelinek; Matthias Niedrig; Andreas Thiel
Journal:  J Immunol       Date:  2015-10-12       Impact factor: 5.422

View more
  22 in total

1.  Yellow Fever: Factors Associated with Death in a Hospital of Reference in Infectious Diseases, São Paulo, Brazil, 2018.

Authors:  Ana Freitas Ribeiro; Roberta Figueiredo Cavalin; Jamal Muhamad Abdul Hamid Suleiman; Jessica Alves da Costa; Marileide Januaria de Vasconcelos; Ceila Maria Sant'Ana Málaque; Jaques Sztajnbok
Journal:  Am J Trop Med Hyg       Date:  2019-07       Impact factor: 2.345

Review 2.  Review of data and knowledge gaps regarding yellow fever vaccine-induced immunity and duration of protection.

Authors:  J Erin Staples; Alan D T Barrett; Annelies Wilder-Smith; Joachim Hombach
Journal:  NPJ Vaccines       Date:  2020-07-06       Impact factor: 7.344

Review 3.  Live Attenuated Yellow Fever 17D Vaccine: A Legacy Vaccine Still Controlling Outbreaks In Modern Day.

Authors:  Natalie D Collins; Alan D T Barrett
Journal:  Curr Infect Dis Rep       Date:  2017-03       Impact factor: 3.725

4.  Seroepidemiology of Dengue, Zika, and Yellow Fever Viruses among Children in the Democratic Republic of the Congo.

Authors:  Alexandra C Willcox; Matthew H Collins; Ramesh Jadi; Corinna Keeler; Jonathan B Parr; Dieudonné Mumba; Melchior Kashamuka; Antoinette Tshefu; Aravinda M de Silva; Steven R Meshnick
Journal:  Am J Trop Med Hyg       Date:  2018-07-05       Impact factor: 2.345

5.  Long-Term Protection of Rhesus Macaques from Zika Virus Reinfection.

Authors:  Gage K Moreno; Christina M Newman; Michelle R Koenig; Mariel S Mohns; Andrea M Weiler; Sierra Rybarczyk; Kim L Weisgrau; Logan J Vosler; Nicholas Pomplun; Nancy Schultz-Darken; Eva Rakasz; Dawn M Dudley; Thomas C Friedrich; David H O'Connor
Journal:  J Virol       Date:  2020-02-14       Impact factor: 5.103

6.  Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.

Authors:  Nicole P Lindsey; Kalanthe A Horiuchi; Corey Fulton; Amanda J Panella; Olga I Kosoy; Jason O Velez; Elizabeth R Krow-Lucal; Marc Fischer; J Erin Staples
Journal:  J Travel Med       Date:  2018-01-01       Impact factor: 8.490

Review 7.  Yellow Fever in Travelers.

Authors:  Annelies Wilder-Smith
Journal:  Curr Infect Dis Rep       Date:  2019-10-31       Impact factor: 3.725

8.  An Atypical Local Vesicular Reaction to the Yellow Fever Vaccine.

Authors:  Robert H Wauters; Camellia L Hernandez; Maureen M Petersen
Journal:  Vaccines (Basel)       Date:  2017-09-19

9.  Persistence of Neutralizing Antibody Responses Among Yellow Fever Virus 17D Vaccinees Living in a Nonendemic Setting.

Authors:  Bettie W Kareko; Brian L Booty; Chad D Nix; Zoe L Lyski; Mark K Slifka; Ian J Amanna; William B Messer
Journal:  J Infect Dis       Date:  2020-06-11       Impact factor: 7.759

10.  Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study.

Authors:  Valéria Valim; Ketty Lysie Libardi Lira Machado; Samira Tatiyama Miyamoto; Arthur Dalmaso Pinto; Priscila Costa Martins Rocha; Erica Vieira Serrano; Valquiria Garcia Dinis; Sônia Alves Gouvêa; João Gabriel Fragoso Dias; Ana Carolina Campi-Azevedo; Andréa Teixeira-Carvalho; Vanessa Peruhype-Magalhães; Ismael Artur da Costa-Rocha; Sheila Maria Barbosa de Lima; Emily Hime Miranda; Gisela Freitas Trindade; Maria de Lourdes de Sousa Maia; Maria Bernadete Renoldi de Oliveira Gavi; Lidia Balarini da Silva; Ruben Horst Duque; Ana Paula Espíndula Gianordoli; Thays Zanon Casagrande; Karine Gadioli Oliveira; Bruna Costa da Mata Moura; Fernanda Nicole-Batista; Luiza Correa Rodrigues; Thalles Brandão Clemente; Enan Sales Magalhães; Maria de Fatima Bissoli; Maria da Penha Gomes Gouvea; Lauro Ferreira da Silva Pinto-Neto; Carolina Zorzanelli Costa; Raquel Altoé Giovelli; Leticia Resende Brandão; Elizandra Tomazela Laurenti Polito; Ingrid de Oliveira Koehlert; Brunela Passos Borjaille; Daniela Bergamim Pereira; Laiza Hombre Dias; Daniela Linhares Merlo; Luiz Fellipe Favoreto Genelhu; Flavia Zon Pretti; Maryella Dos Santos Giacomin; Ana Paula Neves Burian; Francieli Fontana Sutile Tardetti Fantinato; Gecilmara Salviato Pileggi; Lícia Maria Henrique da Mota; Olindo Assis Martins-Filho
Journal:  Front Immunol       Date:  2020-07-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.